Publications - Page 48 sur 57 - RespiFIL - Filière de santé des maladies respiratoires rares

Voici les publications scientifiques relatives aux maladies respiratoires rares auxquelles les membres de la filière ont contribué, classées par groupes de pathologies (depuis juillet 2021).

Hypertension pulmonaire (HTP)
Outcomes of patients with decreased arterial oxyhaemoglobin saturation on pulmonary arterial hypertension drugs

Valentin S, Maurac A, Sitbon O, Beurnier A, Gomez E, Guillaumot A, Textoris L, Fay R, Savale L, Jaïs X, Montani D, Picard F, Mornex JF, Prevot G, Chabot F, Humbert M, Chaouat A.

Eur Respir J. 2021 Nov 4;58(5):2004066.
Hypertension pulmonaire (HTP)
Role of Store-Operated Ca2+ Entry in the Pulmonary Vascular Remodeling Occurring in Pulmonary Arterial Hypertension

Masson B, Montani D, Humbert M, Capuano V, Antigny F.

Biomolecules. 2021 Nov 27;11(12):1781.
Hypertension pulmonaire (HTP)
Sex and gender in pulmonary arterial hypertension

Cheron C, McBride SA, Antigny F, Girerd B, Chouchana M, Chaumais MC, Jaïs X, Bertoletti L, Sitbon O, Weatherald J, Humbert M, Montani D.

Eur Respir Rev. 2021 Nov 8;30(162):200330.
Hypertension pulmonaire (HTP)
Pulmonary hypertension : A rare but severe complication of common variable immunodeficiency

Thoré P, Humbert M, Montani D.

Ann Allergy Asthma Immunol. 2021 Oct;127(4):512-513. Doi: 10.1016/j.anai.2021.06.016.
Hypertension pulmonaire (HTP)
Association between Initial Treatment Strategy and Long-Term Survival in Pulmonary Arterial Hypertension

Boucly A, Savale L, Jaïs X, Bauer F, Bergot E, Bertoletti L, Beurnier A, Bourdin A, Bouvaist H, Bulifon S, Chabanne C, Chaouat A, Cottin V, Dauphin C, Degano B, De Groote P, Favrolt N, Feng Y, Horeau-Langlard D, Jevnikar M, Jutant EM, Liang Z, Magro P, Mauran P, Moceri P, Mornex JF, Palat S, Parent F, Picard F, Pichon J, Poubeau P, Prévot G, Renard S, Reynaud-Gaubert M, Riou M, Roblot P, Sanchez O, Seferian A, Tromeur C, Weatherald J, Simonneau G, Montani D, Humbert M, Sitbon O.

Am J Respir Crit Care Med. 2021 Oct 1;204(7):842-854. Doi: 10.1164/rccm.202009-3698OC.
Hypertension pulmonaire (HTP)
Pulmonary Hypertension in Patients with Common Variable Immunodeficiency

Thoré P, Jaïs X, Savale L, Dorfmuller P, Boucly A, Devilder M, Meyrignac O, Pichon J, Mankikian J, Riou M, Boiffard E, Boissin C, De Groote P, Chabanne C, Gagnadoux F, Bergeron A, Noel N, Sitbon O, Humbert M, Montani D.

J Clin Immunol. 2021 Oct;41(7):1549-1562. Doi: 10.1007/s10875-021-01064-w.
Hypertension pulmonaire (HTP)
Investigating the association between ALK Receptor Tyrosine Kinase inhibitors and pulmonary arterial hypertension: a disproportionality analysis from the WHO pharmacovigilance database

Khouri C, Hlavaty A, Roustit M, Cracowski JL, Chaumais MC, Humbert M, Montani D.

Eur Respir J. 2021 Sep 29:2101576. Doi: 10.1183/13993003.01576-2021.
Hypertension pulmonaire (HTP)
Mendelian randomisation and experimental medicine approaches to IL-6 as a drug target in PAH

Toshner M, Church C, Harbaum L, Rhodes C, Villar Moreschi SS, Liley J, Jones R, Arora A, Batai K, Desai AA, Coghlan JG, Gibbs JSR, Gor D, Gräf S, Harlow L, Hernandez-Sanchez J, Howard LS, Humbert M, Karnes J, Kiely DG, Kittles R, Knightbridge E, Lam B, Lutz KA, Nichols WC, Pauciulo MW, Pepke-Zaba J, Suntharalingam J, Soubrier F, Trembath RC, Schwantes-An TL, Wort SJ, Wilkins M, Gaine S, Morrell NW, Corris PA.

Eur Respir J. 2021 Sep 29:2002463. Doi: 10.1183/13993003.02463-2020.
Hypertension pulmonaire (HTP)
Severe pulmonary hypertension associated with chronic obstructive pulmonary disease: A prospective French multicenter cohort

Dauriat G, Reynaud-Gaubert M, Cottin V, Lamia B, Montani D, Canuet M, Boissin C, Tromeur C, Chaouat A, Degano B, Bergot E, Sanchez O, Prevot G, Sitbon O, Thabut G, Belhadi D, de Beauregard YC, Bencherif A, Humbert M, Simonneau G, Laouenan C, Mal H.

J Heart Lung Transplant. 2021 Sep;40(9):1009-1018. Doi: 10.1016/j.healun.2021.04.021.
Hypertension pulmonaire (HTP)
A CELSR1 variant in a patient with pulmonary arterial hypertension

Eyries M, Girerd B, Savale L, Soubrier F, Humbert M, Montani D.

Clin Genet. 2021 Aug 25. Doi: 10.1111/cge.14046.

FILTRER :

Par mot clé

Par maladies

Réinitialiser les filtres

Outcomes of patients with decreased arterial oxyhaemoglobin saturation on pulmonary arterial hypertension drugs

Role of Store-Operated Ca2+ Entry in the Pulmonary Vascular Remodeling Occurring in Pulmonary Arterial Hypertension

Sex and gender in pulmonary arterial hypertension

Pulmonary hypertension : A rare but severe complication of common variable immunodeficiency

Association between Initial Treatment Strategy and Long-Term Survival in Pulmonary Arterial Hypertension

Pulmonary Hypertension in Patients with Common Variable Immunodeficiency

Investigating the association between ALK Receptor Tyrosine Kinase inhibitors and pulmonary arterial hypertension: a disproportionality analysis from the WHO pharmacovigilance database

Mendelian randomisation and experimental medicine approaches to IL-6 as a drug target in PAH

Severe pulmonary hypertension associated with chronic obstructive pulmonary disease: A prospective French multicenter cohort

A CELSR1 variant in a patient with pulmonary arterial hypertension